Expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression

Gynecological Endocrinology

Volumn 24, Issue 6, 2008, Pages 331-338

  Schubert, Antje ^a   Schulz, Hiltrud ^a   Emons, Günter ^a   Gründker, Carsten ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Department of Gynecology and Obstetrics ^*  (Germany)

Author keywords

Bone; Breast cancer; GnRH; Metastasis; OPG; RANKL

Indexed keywords

GONADORELIN; GONADORELIN RECEPTOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRADUCTAL CARCINOMA; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; OSTEOBLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTORS, LHRH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIPTORELIN;

EID: 46349083073     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802095845     Document Type: Article

References (22)

1. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005;5(Suppl 2):S46-S53.
2. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005;10:169-180.
3. Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989;3:137-147.
4. Baumann KH, Kiesel L, Kaufmann M, Bastert G, Runnebaum B. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 1993;25:37-46.
5. Moriya T, Suzuki T, Pilichowska M, Ariga N, Kimura N, Ouchi N, Nagura H, Sasano H. Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma. Pathol Int 2001;51:333-337.
6. Mangia A, Tommasi S, Reshkin SJ, Simone G, Stea B, Schittulli F, Paradiso A. Gonadotropin releasing hormone receptor expression in primary breast cancer: comparison of immunohistochemical, radioligand and Western blot analyses. Oncol Rep 2002;9:1127-1132.
7. Günthert AR, Gründker C, Olota A, Lasche J, Eicke N, Emons G. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. Eur J Endocrinol 2005;153:613-625.
8. von Alten J, Fister S, Schulz H, Viereck V, Frosch KH, Emons G, Gründker C. GnRH analogs reduce invasiveness of human breast cancer cells. Breast Cancer Res Treat 2006;100:13-21.
9. Viereck V, Gründker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. J Cell Biochem 2002;84:725-735.
10. Siggelkow H, Rebenstorff K, Kurre W, Niedhart C, Engel I, Schulz H, Atkinson MJ, Hüfner M. Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem 1999;75:22-35.
11. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
12. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
13. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179.
14. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-1508.
15. Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MW, Holen I. Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J Clin Pathol 2006;59:716-720.
16. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000;103:41-50.
17. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-615.
18. Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003;97(3 Suppl):834-839.
19. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-696.
20. Yun HJ, Jo DY. Production of stromal cell-derived factor-1 (SDF-1) and expression of CXCR4 in human bone marrow endothelial cells. J Korean Med Sci 2003;18:679-685.
21. Aust G, Steinert M, Kiessling S, Kamprad M, Simchen C. Reduced expression of stromal-derived factor 1 in autonomous thyroid adenomas and its regulation in thyroid-derived cells. J Clin Endocrinol Metab 2001;86:3368-3376.
22. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 2006;60:273-276.